ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
MaxCyte Begins Dosing in First Clinical Trial in Solid Tumors
americanpharmaceuticalreview
October 12, 2018MaxCyte announced the first patient has been dosed in its Phase I dose-escalation clinical trial in the United States with the company's lead wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11. The study is designed to evaluate MC
Pharma Sources Insight January 2025
